Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Marie-Claude Fournié-Zaluski

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Living Beings

Genes & Molecular Sequences

Amino Acid Sequence

Concepts & Ideas

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
92
Roques, Bernard
20
Noble, Florence
16
Turcaud, Serge
14
Coric, Pascale
10
Maldonado, Rafael
8
Michel, Jean-Baptiste
6
Meudal, Hervé
6
Chen, Huixiong
6
Valverde, O
5
Besson, Jean-Marie
5
Beaumont, A
5
Cornille, F
5
de Rocquigny, Hugues
5
Daugé, Valérie
5
Le Guen, Stéphanie

Sign-in to see all Coauthors

Publications

TOP 3
González-Rodríguez Sara; Pevida Marta; Roques Bernard P; Fournié-Zaluski Marie-Claude; Hidalgo Agustín; Menéndez Luis; Baamonde Ana
Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors.
Fournié-Zaluski Marie Claude; Poras Hervé; Roques Bernard P; Nakajima Yoshitaka; Ito Kiyoshi; Yoshimoto Tadashi
Structure of aminopeptidase N from Escherichia coli complexed with the transition-state analogue aminophosphinic inhibitor PL250.
Poras Hervé; Ouimet Tanja; Orng Sou-Vinh; Fournié-Zaluski Marie-Claude; Popoff Michel R; Roques Bernard P
Detection and quantification of botulinum neurotoxin type a by a novel rapid in vitro fluorimetric assay.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Marie-Claude Fournié-Zaluski (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: González-Rodríguez Sara; Pevida Marta; Roques Bernard P; Fournié-Zaluski Marie-Claude; Hidalgo Agustín; Menéndez Luis; Baamonde Ana
Involvement of enkephalins in the inhibition of osteosarcoma-induced thermal hyperalgesia evoked by the blockade of peripheral P2X3 receptors.
Neuroscience letters 2009;465(3):285-9.
2009: Fournié-Zaluski Marie Claude; Poras Hervé; Roques Bernard P; Nakajima Yoshitaka; Ito Kiyoshi; Yoshimoto Tadashi
Structure of aminopeptidase N from Escherichia coli complexed with the transition-state analogue aminophosphinic inhibitor PL250.
Acta crystallographica. Section D, Biological crystallography 2009;65(Pt 8):814-22.
2009: Poras Hervé; Ouimet Tanja; Orng Sou-Vinh; Fournié-Zaluski Marie-Claude; Popoff Michel R; Roques Bernard P
Detection and quantification of botulinum neurotoxin type a by a novel rapid in vitro fluorimetric assay.
Applied and environmental microbiology 2009;75(13):4382-90.
2009: Sevalle Jean; Amoyel Audrey; Robert Philippe; Fournié-Zaluski Marie-Claude; Roques Bernard; Checler Frédéric
Aminopeptidase A contributes to the N-terminal truncation of amyloid beta-peptide.
Journal of neurochemistry 2009;109(1):248-56.
2008: Menéndez Luis; Hidalgo Agustín; Meana Alvaro; Poras Hervé; Fournié-Zaluski Marie-Claude; Roques Bernard P; Baamonde Ana
Inhibition of osteosarcoma-induced thermal hyperalgesia in mice by the orally active dual enkephalinase inhibitor PL37. Potentiation by gabapentin.
European journal of pharmacology 2008;596(1-3):50-5.
2008: Tholander Fredrik; Muroya Ayumo; Roques Bernard-Pierre; Fournié-Zaluski Marie-Claude; Thunnissen Marjolein M G M; Haeggström Jesper Z
Structure-based dissection of the active site chemistry of leukotriene A4 hydrolase: implications for M1 aminopeptidases and inhibitor design.
Chemistry & biology 2008;15(9):920-9.
2005: Raguin Olivier; Fournié-Zaluski Marie-Claude; Romieu Anthony; Pèlegrin André; Chatelet François; Pélaprat Didier; Barbet Jacques; Roques Bernard P; Gruaz-Guyon Anne
A labeled neutral endopeptidase inhibitor as a potential tool for tumor diagnosis and prognosis.
Angewandte Chemie (International ed. in English) 2005;44(26):4058-61.
2005: Inguimbert N; Coric P; Dhotel H; Bonnard E; Llorens-Cortes C; Mota N; Fournié-Zaluski M-C; Roques B-P
Synthesis and in vitro activities of new non-peptidic APA inhibitors.
The journal of peptide research : official journal of the American Peptide Society 2005;65(2):175-88.
2004: Stragier Bart; Sarre Sophie; Vanderheyden Patrick; Vauquelin Georges; Fournié-Zaluski Marie-Claude; Ebinger Guy; Michotte Yvette
Metabolism of angiotensin II is required for its in vivo effect on dopamine release in the striatum of the rat.
Journal of neurochemistry 2004;90(5):1251-7.
2004: Jardinaud Fanny; Banisadr Ghasal; Noble Florence; Mélik-Parsadaniantz Stéphane; Chen Huixiong; Dugave Christophe; Laplace Hervé; Rostène William; Fournié-Zaluski Marie-Claude; Roques Bernard P; Popovici Théodora
Ontogenic and adult whole body distribution of aminopeptidase N in rat investigated by in vitro autoradiography.
Biochimie 2004;86(2):105-13.
2004: Inguimbert N; Poras H; Dhotel H; Beslot F; Scalbert E; Bennejean C; Renard P; Fournié-Zaluski M-C; Roques B-P
In vivo properties of thiol inhibitors of the three vasopeptidases NEP, ACE and ECE are improved by introduction of a 7-azatryptophan in P2' position.
The journal of peptide research : official journal of the American Peptide Society 2004;63(2):99-107.
2003: Anne Christine; Turcaud Serge; Quancard Jean; Teffo Franck; Meudal Hervé; Fournié-Zaluski Marie-Claude; Roques Bernard P
Development of potent inhibitors of botulinum neurotoxin type B.
Journal of medicinal chemistry 2003;46(22):4648-56.
2003: Le Guen Stéphanie; Mas Nieto Magdalena; Canestrelli Corinne; Chen Huixiong; Fournié-Zaluski Marie-Claude; Cupo Annie; Maldonado Rafaël; Roques Bernard P; Noble Florence
Pain management by a new series of dual inhibitors of enkephalin degrading enzymes: long lasting antinociceptive properties and potentiation by CCK2 antagonist or methadone.
Pain 2003;104(1-2):139-48.
2003: Selkti Mohamed; Tomas Alain; Gaucher Jean-François; Prangé Thierry; Fournié-Zaluski Marie-Claude; Chen Huixiong; Roques Bernard-Pierre
Interactions of a new alpha-aminophosphinic derivative inside the active site of TLN (thermolysin): a model for zinc-metalloendopeptidase inhibition.
Acta crystallographica. Section D, Biological crystallography 2003;59(Pt 7):1200-5.
2003: Le Guen Stéphanie; Catheline Gwénaëlle; Fournié-Zaluski Marie Claude; Roques Bernard Pierre; Besson Jean Marie; Buritova Jaroslava
Further evidence for the interaction of mu- and delta-opioid receptors in the antinociceptive effects of the dual inhibitor of enkephalin catabolism, RB101(S). A spinal c-Fos protein study in the rat under carrageenin inflammation.
Brain research 2003;967(1-2):106-12.
2003: Arbin Valérie; Claperon Nicole; Fournié-Zaluski Marie-Claude; Roques Bernard P; Peyroux Jacques
Effects of dual angiotensin-converting enzyme and neutral endopeptidase 24-11 chronic inhibition by mixanpril on insulin sensitivity in lean and obese Zucker rats.
Journal of cardiovascular pharmacology 2003;41(2):254-64.
2003: Buritova Jaroslava; Le Guen Stéphanie; Fournié-Zaluski Marie-Claude; Roques Bernard P; Besson Jean-Marie
Antinociceptive effects of RB101(S), a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by (+)-HA966, a functional NMDA receptor antagonist: a c-Fos study in the rat spinal cord.
European journal of pain (London, England) 2003;7(3):241-9.
2002: Inguimbert Nicolas; Poras Hervé; Teffo Franck; Beslot Françoise; Selkti Mohamed; Tomas Alain; Scalbert Elizabeth; Bennejean Caroline; Renard Pierre; Fournié-Zaluski Marie-Claude; Roques Bernard-Pierre
N-[2-(Indan-1-yl)-3-mercapto-propionyl] amino acids as highly potent inhibitors of the three vasopeptidases (NEP, ACE, ECE): In vitro and In vivo activities.
Bioorganic & medicinal chemistry letters 2002;12(15):2001-5.
2002: Benoist Jean-Michel; Keime Florence; Montagne Jacqueline; Noble Florence; Fournié-Zaluski Marie-Claude; Roques Bernard P; Willer Jean-Claude; Le Bars Daniel
Depressant effect on a C-fibre reflex in the rat, of RB101, a dual inhibitor of enkephalin-degrading enzymes.
European journal of pharmacology 2002;445(3):201-10.
2002: Le Guen Stéphanie; Noble Florence; Fournié-Zaluski Marie-Claude; Roques Bernard Pierre; Besson Jean-Marie; Buritova Jaroslava
RB101(S), a dual inhibitor of enkephalinases does not induce antinociceptive tolerance, or cross-tolerance with morphine: a c-Fos study at the spinal level.
European journal of pharmacology 2002;441(3):141-50.
2002: Inguimbert Nicolas; Coric Pascale; Poras Hervé; Meudal Hervé; Teffot Franck; Fournié-Zaluski Marie-Claude; Roques Bernard P
Toward an optimal joint recognition of the S1' subsites of endothelin converting enzyme-1 (ECE-1), angiotensin converting enzyme (ACE), and neutral endopeptidase (NEP).
Journal of medicinal chemistry 2002;45(7):1477-86.
2001: Chen H; Noble F; Roques B P; Fournié-Zaluski M C
Long lasting antinociceptive properties of enkephalin degrading enzyme (NEP and APN) inhibitor prodrugs.
Journal of medicinal chemistry 2001;44(21):3523-30.
2001: Nieto M M; Wilson J; Walker J; Benavides J; Fournié-Zaluski M C; Roques B P; Noble F
Facilitation of enkephalins catabolism inhibitor-induced antinociception by drugs classically used in pain management.
Neuropharmacology 2001;41(4):496-506.
2001: Arbin V; Claperon N; Fournié-Zaluski M C; Roques B P; Peyroux J
Acute effect of the dual angiotensin-converting enzyme and neutral endopeptidase 24-11 inhibitor mixanpril on insulin sensitivity in obese Zucker rat.
British journal of pharmacology 2001;133(4):495-502.
2001: Valverde O; Noble F; Beslot F; Daugé V; Fournié-Zaluski M C; Roques B P
Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect.
The European journal of neuroscience 2001;13(9):1816-24.
2000: Roques B P; Anne C; Turcaud S; Fournié-Zaluski M C
Mechanism of action of clostridial neurotoxins and rational inhibitor design.
Biology of the cell / under the auspices of the European Cell Biology Organization 2000;92(6):445-7.
2000: Arbin V; Claperon N; Fournié-Zaluski M C; Roques B P; Peyroux J
Effects of combined neutral endopeptidase 24-11 and angiotensin-converting enzyme inhibition on femoral vascular conductance in streptozotocin-induced diabetic rats.
British journal of pharmacology 2000;130(6):1297-304.
2000: Chen H; Noble F; Mothé A; Meudal H; Coric P; Danascimento S; Roques B P; George P; Fournié-Zaluski M C
Phosphinic derivatives as new dual enkephalin-degrading enzyme inhibitors: synthesis, biological properties, and antinociceptive activities.
Journal of medicinal chemistry 2000;43(7):1398-408.
2000: Noble F; Luciani N; Da Nascimento S; Laï-Kuen R; Bischoff L; Chen H; Fournié-Zaluski M C; Roques B P
Binding properties of a highly potent and selective iodinated aminopeptidase N inhibitor appropriate for radioautography.
FEBS letters 2000;467(1):81-6.
1999: David C; Bischoff L; Meudal H; Mothé A; De Mota N; DaNascimento S; Llorens-Cortes C; Fournié-Zaluski M C; Roques B P
Investigation of subsite preferences in aminopeptidase A (EC 3.4.11.7) led to the design of the first highly potent and selective inhibitors of this enzyme.
Journal of medicinal chemistry 1999;42(25):5197-211.
1999: Gaucher J F; Selkti M; Tiraboschi G; Prangé T; Roques B P; Tomas A; Fournié-Zaluski M C
Crystal structures of alpha-mercaptoacyldipeptides in the thermolysin active site: structural parameters for a Zn monodentation or bidentation in metalloendopeptidases.
Biochemistry 1999;38(39):12569-76.
1999: Ramboarina S; Morellet N; Fournié-Zaluski M C; Roques B P;
Structural investigation on the requirement of CCHH zinc finger type in nucleocapsid protein of human immunodeficiency virus 1.
Biochemistry 1999;38(30):9600-7.
1999: Le Guen S; Honoré P; Catheline G; Fournié-Zaluski M C; Roques B P; Besson J M
The effects of RB101, a mixed inhibitor of enkephalin-catabolizing enzymes, on carrageenin-induced spinal c-Fos expression are completely blocked by beta-funaltrexamine, a selective mu-opioid receptor antagonist.
Brain research 1999;834(1-2):200-6.
1999: Chen H; Roques B P; Fournié-Zaluski M C
Design of the first highly potent and selective aminopeptidase N (EC 3.4.11.2) inhibitor.
Bioorganic & medicinal chemistry letters 1999;9(11):1511-6.
1999: Réaux A; de Mota N; Zini S; Cadel S; Fournié-Zaluski M C; Roques B P; Corvol P; Llorens-Cortès C
PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III.
Neuroendocrinology 1999;69(5):370-6.
1999: Druillennec S; Dong C Z; Escaich S; Gresh N; Bousseau A; Roques B P; Fournié-Zaluski M C
A mimic of HIV-1 nucleocapsid protein impairs reverse transcription and displays antiviral activity.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(9):4886-91.
1999: Druillennec S; Meudal H; Roques B P; Fournié-Zaluski M C
Nucleomimetic strategy for the inhibition of HIV-1 nucleocapsid protein NCp7 activities.
Bioorganic & medicinal chemistry letters 1999;9(4):627-32.
1999: Martin L; Cornille F; Turcaud S; Meudal H; Roques B P; Fournié-Zaluski M C
Metallopeptidase inhibitors of tetanus toxin: A combinatorial approach.
Journal of medicinal chemistry 1999;42(3):515-25.
1999: Noble F; Fournié-Zaluski M C; Roques B P
[Enkephalin catabolism inhibitors and antalgics of the future: from preclinical research to clinical trials]
Thérapie 1999;54(1):121-33.
1998: Morellet N; Déméné H; Teilleux V; Huynh-Dinh T; de Rocquigny H; Fournié-Zaluski M C; Roques B P
Structure of the complex between the HIV-1 nucleocapsid protein NCp7 and the single-stranded pentanucleotide d(ACGCC).
Journal of molecular biology 1998;283(2):419-34.
1998: Chansel D; Czekalski S; Vandermeersch S; Ruffet E; Fournié-Zaluski M C; Ardaillou R
Characterization of angiotensin IV-degrading enzymes and receptors on rat mesangial cells.
The American journal of physiology 1998;275(4 Pt 2):F535-42.
1998: Ramboarina S; Morellet N; Petitjean P; Roques B P; Fournié-Zaluski M C
Model of the complex formed between the H2 domain of the TATA box binding protein and the L(281-301) fragment of the human transcription factor TFIIA.
Protein engineering 1998;11(9):729-38.
1998: Ortega-Alvaro A; Chover-Gonzalez A J; Lai-Kuen R; Mico J A; Gibert-Rahola J; Fournié-Zaluski M C; Roques B P; Maldonado R
Antinociception produced by the peptidase inhibitor, RB 101, in rats with adrenal medullary transplant into the spinal cord.
European journal of pharmacology 1998;356(2-3):139-48.
1998: Martin L; Cornille F; Coric P; Roques B P; Fournié-Zaluski M C
Beta-amino-thiols inhibit the zinc metallopeptidase activity of tetanus toxin light chain.
Journal of medicinal chemistry 1998;41(18):3450-60.
1998: Zini S; Demassey Y; Fournié-Zaluski M C; Bischoff L; Corvol P; Llorens-Cortès C; Sanderson P
Inhibition of vasopressinergic neurons by central injection of a specific aminopeptidase A inhibitor.
Neuroreport 1998;9(5):825-8.
1998: Luciani N; Marie-Claire C; Ruffet E; Beaumont A; Roques B P; Fournié-Zaluski M C
Characterization of Glu350 as a critical residue involved in the N-terminal amine binding site of aminopeptidase N (EC 3.4.11.2): insights into its mechanism of action.
Biochemistry 1998;37(2):686-92.
1997: Noble F; Smadja C; Valverde O; Maldonado R; Coric P; Turcaud S; Fournié-Zaluski M C; Roques B P
Pain-suppressive effects on various nociceptive stimuli (thermal, chemical, electrical and inflammatory) of the first orally active enkephalin-metabolizing enzyme inhibitor RB 120.
Pain 1997;73(3):383-91.
1997: Marie-Claire C; Ruffet E; Antonczak S; Beaumont A; O'Donohue M; Roques B P; Fournié-Zaluski M C
Evidence by site-directed mutagenesis that arginine 203 of thermolysin and arginine 717 of neprilysin (neutral endopeptidase) play equivalent critical roles in substrate hydrolysis and inhibitor binding.
Biochemistry 1997;36(45):13938-45.
1997: Dong C Z; De Rocquigny H; Rémy E; Mellac S; Fournié-Zaluski M C; Roques B P
Synthesis and biological activities of fluorescent acridine-containing HIV-1 nucleocapsid proteins for investigation of nucleic acid-NCp7 interactions.
The journal of peptide research : official journal of the American Peptide Society 1997;50(4):269-78.
1997: Smadja C; Ruiz F; Coric P; Fournié-Zaluski M C; Roques B P; Maldonado R
CCK-B receptors in the limbic system modulate the antidepressant-like effects induced by endogenous enkephalins.
Psychopharmacology 1997;132(3):227-36.
1997: Honore P; Buritova J; Fournié-Zaluski M C; Roques B P; Besson J M
Antinociceptive effects of RB101, a complete inhibitor of enkephalin-catabolizing enzymes, are enhanced by a cholecystokinin type B receptor antagonist, as revealed by noxiously evoked spinal c-Fos expression in rats.
The Journal of pharmacology and experimental therapeutics 1997;281(1):208-17.
1996: Hernando F; Fuentes J A; Fournié-Zaluski M C; Roques B P; Ruiz-Gayo M
Antidepressant-like effects of CCK(B) receptor antagonists: involvement of the opioid system.
European journal of pharmacology 1996;318(2-3):221-9.
1996: Soleilhac J M; Cornille F; Martin L; Lenoir C; Fournié-Zaluski M C; Roques B P
A sensitive and rapid fluorescence-based assay for determination of tetanus toxin peptidase activity.
Analytical biochemistry 1996;241(1):120-7.
1996: Valverde O; Fournié-Zaluski M C; Roques B P; Maldonado R
Similar involvement of several brain areas in the antinociception of endogenous and exogenous opioids.
European journal of pharmacology 1996;312(1):15-25.
1996: Ruiz F; Fournié-Zaluski M C; Roques B P; Maldonado R
Similar decrease in spontaneous morphine abstinence by methadone and RB 101, an inhibitor of enkephalin catabolism.
British journal of pharmacology 1996;119(1):174-82.
1996: Daugé V; Mauborgne A; Cesselin F; Fournié-Zaluski M C; Roques B P
The dual peptidase inhibitor RB101 induces a long-lasting increase in the extracellular level of Met-enkephalin-like material in the nucleus accumbens of freely moving rats.
Journal of neurochemistry 1996;67(3):1301-8.
1996: Gonzalez W; Beslot F; Laboulandine I; Fournié-Zaluski M C; Roques B P; Michel J B
Inhibition of both angiotensin-converting enzyme and neutral endopeptidase by S21402 (RB105) in rats with experimental myocardial infarction.
The Journal of pharmacology and experimental therapeutics 1996;278(2):573-81.
1996: Migaud M; Durieux C; Viereck J; Soroca-Lucas E; Fournié-Zaluski M C; Roques B P
The in vivo metabolism of cholecystokinin (CCK-8) is essentially ensured by aminopeptidase A.
Peptides 1996;17(4):601-7.
1995: Valverde O; Blommaert A G; Fournié-Zaluski M C; Roques B P; Maldonado R
Weak tolerance to the antinociceptive effect induced by the association of a peptidase inhibitor and a CCKB receptor antagonist.
European journal of pharmacology 1995;286(1):79-93.
1995: Cornille F; Deloye F; Fournié-Zaluski M C; Roques B P; Poulain B
Inhibition of neurotransmitter release by synthetic proline-rich peptides shows that the N-terminal domain of vesicle-associated membrane protein/synaptobrevin is critical for neuro-exocytosis.
The Journal of biological chemistry 1995;270(28):16826-32.
1995: Beaumont A; O'Donohue M J; Paredes N; Rousselet N; Assicot M; Bohuon C; Fournié-Zaluski M C; Roques B P
The role of histidine 231 in thermolysin-like enzymes. A site-directed mutagenesis study.
The Journal of biological chemistry 1995;270(28):16803-8.
1995: Gonzalez Vera W; Fournié-Zaluski M C; Pham I; Laboulandine I; Roques B P; Michel J B
Hypotensive and natriuretic effects of RB 105, a new dual inhibitor of angiotensin converting enzyme and neutral endopeptidase in hypertensive rats.
The Journal of pharmacology and experimental therapeutics 1995;272(1):343-51.
1995: Noble F; Blommaert A; Fournié-Zaluski M C; Roques B P
A selective CCKB receptor antagonist potentiates, mu-, but not delta-opioid receptor-mediated antinociception in the formalin test.
European journal of pharmacology 1995;273(1-2):145-51.
1995: Roques B P; Noble F; Crine P; Fournié-Zaluski M C
Inhibitors of neprilysin: design, pharmacological and clinical applications.
Methods in enzymology 1995;248():263-83.
1995: Pham I; Lévy B; Fournié-Zaluski M C; Poitevin P; Roques B P; Michel J B
Acute hemodynamic effects of combined inhibition of neutral endopeptidase and angiotensin converting enzyme in spontaneously hypertensive rats.
Fundamental & clinical pharmacology 1995;9(2):153-60.
1994: Déméné H; Dong C Z; Ottmann M; Rouyez M C; Jullian N; Morellet N; Mely Y; Darlix J L; Fournié-Zaluski M C; Saragosti S
1H NMR structure and biological studies of the His23-->Cys mutant nucleocapsid protein of HIV-1 indicate that the conformation of the first zinc finger is critical for virus infectivity.
Biochemistry 1994;33(39):11707-16.
1994: Chauvel E N; Llorens-Cortès C; Coric P; Wilk S; Roques B P; Fournié-Zaluski M C
Differential inhibition of aminopeptidase A and aminopeptidase N by new beta-amino thiols.
Journal of medicinal chemistry 1994;37(18):2950-7.
1994: Maldonado R; Valverde O; Turcaud S; Fournié-Zaluski M C; Roques B P
Antinociceptive response induced by mixed inhibitors of enkephalin catabolism in peripheral inflammation.
Pain 1994;58(1):77-83.
1994: Fournié-Zaluski M C; Gonzalez W; Turcaud S; Pham I; Roques B P; Michel J B
Dual inhibition of angiotensin-converting enzyme and neutral endopeptidase by the orally active inhibitor mixanpril: a potential therapeutic approach in hypertension.
Proceedings of the National Academy of Sciences of the United States of America 1994;91(9):4072-6.
1994: Fournié-Zaluski M C; Coric P; Turcaud S; Rousselet N; Gonzalez W; Barbe B; Pham I; Jullian N; Michel J B; Roques B P
New dual inhibitors of neutral endopeptidase and angiotensin-converting enzyme: rational design, bioavailability, and pharmacological responses in experimental hypertension.
Journal of medicinal chemistry 1994;37(8):1070-83.
1994: Chauvel E N; Coric P; Llorens-Cortès C; Wilk S; Roques B P; Fournié-Zaluski M C
Investigation of the active site of aminopeptidase A using a series of new thiol-containing inhibitors.
Journal of medicinal chemistry 1994;37(9):1339-46.
1994: Noble F; Coric P; Turcaud S; Fournié-Zaluski M C; Roques B P
Assessment of physical dependence after continuous perfusion into the rat jugular vein of the mixed inhibitor of enkephalin-degrading enzymes, RB 101.
European journal of pharmacology 1994;253(3):283-7.
1994: Durieux C; Derrien M; Maldonado R; Valverde O; Blommaert A; Fournié-Zaluski M C; Roques B P
CCK-B antagonists exhibit antidepressant-like effects and potentiate endogenous enkephalin analgesia. Correlation with in vivo binding affinities and brain penetration.
Annals of the New York Academy of Sciences 1994;713():355-7.
1994: Noble F; Fournié-Zaluski M C; Roques B P
Paradoxical analgesia induced by low doses of naloxone is not potentiated by complete inhibition of enkephalin degradation.
Neuropharmacology 1994;33(1):135-40.
1993: Pham I; Gonzalez W; el Amrani A I; Fournié-Zaluski M C; Philippe M; Laboulandine I; Roques B P; Michel J B
Effects of converting enzyme inhibitor and neutral endopeptidase inhibitor on blood pressure and renal function in experimental hypertension.
The Journal of pharmacology and experimental therapeutics 1993;265(3):1339-47.
1993: Noble F; Fournié-Zaluski M C; Roques B P
Unlike morphine the endogenous enkephalins protected by RB101 are unable to establish a conditioned place preference in mice.
European journal of pharmacology 1993;230(2):139-49.
1993: Mely Y; de Rocquigny H; Piémont E; Déméné H; Jullian N; Fournié-Zaluski M C; Roques B; Gérard D
Influence of the N- and C-terminal chains on the zinc-binding and conformational properties of the central zinc-finger structure of Moloney murine leukaemia virus nucleocapsid protein: a steady-state and time-resolved fluorescence study.
Biochimica et biophysica acta 1993;1161(1):6-18.
1993: Gomez-Monterrey I; Turcaud S; Lucas E; Bruetschy L; Roques B P; Fournié-Zaluski M C
Exploration of neutral endopeptidase active site by a series of new thiol-containing inhibitors.
Journal of medicinal chemistry 1993;36(1):87-94.
1992: Pham I; el Amrani A I; Fournié-Zaluski M C; Corvol P; Roques B; Michel J B
Effects of the selective neutral endopeptidase inhibitor, retrothiorphan, on renal function and blood pressure in conscious normotensive Wistar and hypertensive DOCA-salt rats.
Journal of cardiovascular pharmacology 1992;20(6):847-57.
1992: Noble F; Coric P; Fournié-Zaluski M C; Roques B P
Lack of physical dependence in mice after repeated systemic administration of the mixed inhibitor prodrug of enkephalin-degrading enzymes, RB101.
European journal of pharmacology 1992;223(1):91-6.
1992: Noble F; Turcaud S; Fournié-Zaluski M C; Roques B P
Repeated systemic administration of the mixed inhibitor of enkephalin-degrading enzymes, RB101, does not induce either antinociceptive tolerance or cross-tolerance with morphine.
European journal of pharmacology 1992;223(1):83-9.
1992: Ruiz-Gayo M; Durieux C; Fournié-Zaluski M C; Roques B P
Stimulation of delta-opioid receptors reduces the in vivo binding of the cholecystokinin (CCK)-B-selective agonist [3H]pBC 264: evidence for a physiological regulation of CCKergic systems by endogenous enkephalins.
Journal of neurochemistry 1992;59(5):1805-11.
1992: De Rocquigny H; Gabus C; Vincent A; Fournié-Zaluski M C; Roques B; Darlix J L
Viral RNA annealing activities of human immunodeficiency virus type 1 nucleocapsid protein require only peptide domains outside the zinc fingers.
Proceedings of the National Academy of Sciences of the United States of America 1992;89(14):6472-6.
1992: Fournié-Zaluski M C; Soleilhac J M; Turcaud S; Laï-Kuen R; Crine P; Beaumont A; Roques B P
Development of [125I]RB104, a potent inhibitor of neutral endopeptidase 24.11, and its use in detecting nanogram quantities of the enzyme by "inhibitor gel electrophoresis".
Proceedings of the National Academy of Sciences of the United States of America 1992;89(14):6388-92.
1992: Fournié-Zaluski M C; Coric P; Turcaud S; Lucas E; Noble F; Maldonado R; Roques B P
"Mixed inhibitor-prodrug" as a new approach toward systemically active inhibitors of enkephalin-degrading enzymes.
Journal of medicinal chemistry 1992;35(13):2473-81.
1992: Baamonde A; Daugé V; Ruiz-Gayo M; Fulga I G; Turcaud S; Fournié-Zaluski M C; Roques B P
Antidepressant-type effects of endogenous enkephalins protected by systemic RB 101 are mediated by opioid delta and dopamine D1 receptor stimulation.
European journal of pharmacology 1992;216(2):157-66.
1992: Maldonado R; Fournié-Zaluski M C; Roques B P
Attenuation of the morphine withdrawal syndrome by inhibition of catabolism of endogenous enkephalins in the periaqueductal gray matter.
Naunyn-Schmiedeberg's archives of pharmacology 1992;345(4):466-72.
1992: Soleilhac J M; Lucas E; Beaumont A; Turcaud S; Michel J B; Ficheux D; Fournié-Zaluski M C; Roques B P
A 94-kDa protein, identified as neutral endopeptidase-24.11, can inactivate atrial natriuretic peptide in the vascular endothelium.
Molecular pharmacology 1992;41(4):609-14.
1992: Fournié-Zaluski M C; Coric P; Turcaud S; Bruetschy L; Lucas E; Noble F; Roques B P
Potent and systemically active aminopeptidase N inhibitors designed from active-site investigation.
Journal of medicinal chemistry 1992;35(7):1259-66.
1991: de Rocquigny H; Ficheux D; Gabus C; Fournié-Zaluski M C; Darlix J L; Roques B P
First large scale chemical synthesis of the 72 amino acid HIV-1 nucleocapsid protein NCp7 in an active form.
Biochemical and biophysical research communications 1991;180(2):1010-8.
1991: Mely Y; Cornille F; Fournié-Zaluski M C; Darlix J L; Roques B P; Gérard D
Investigation of zinc-binding affinities of Moloney murine leukemia virus nucleocapsid protein and its related zinc finger and modified peptides.
Biopolymers 1991;31(7):899-906.
1991: Schmidt C; Peyroux J; Noble F; Fournié-Zaluski M C; Roques B P
Analgesic responses elicited by endogenous enkephalins (protected by mixed peptidase inhibitors) in a variety of morphine-sensitive noxious tests.
European journal of pharmacology 1991;192(2):253-62.
1990: Roques B P; Gacel G; Daugé V; Baamonde A; Calenco G; Turcaud S; Coric P; Fournié-Zaluski M C
Novel approaches in the development of new analgesics.
Neurophysiologie clinique = Clinical neurophysiology 1990;20(5):369-87.
1989: Xie J; Soleilhac J M; Renwart N; Peyroux J; Roques B P; Fournié-Zaluski M C
Inhibitors of the enkephalin degrading enzymes. Modulation of activity of hydroxamate containing compounds by modifications of the C-terminal residue.
International journal of peptide and protein research 1989;34(3):246-55.
1989: Belleney J; Gacel G; Fournié-Zaluski M C; Maigret B; Roques B P
Delta opioid receptor selectivity induced by conformational constraints in linear enkephalin-related peptides: 1H 400-MHz NMR study and theoretical calculations.
Biochemistry 1989;28(18):7392-400.
1989: Xie J; Soleilhac J M; Schmidt C; Peyroux J; Roques B P; Fournié-Zaluski M C
New kelatorphan-related inhibitors of enkephalin metabolism: improved antinociceptive properties.
Journal of medicinal chemistry 1989;32(7):1497-503.
1989: Fournié-Zaluski M C; Hernandez J F; Soleilhac J M; Renwart N; Peyroux J; Xie J; Roques B P
Enkephalin-degrading enzyme inhibitors. Crucial role of the C-terminal residue on the inhibitory potencies of retro-hydroxamate dipeptides.
International journal of peptide and protein research 1989;33(2):146-53.
1988: Hernandez J F; Soleilhac J M; Roques B P; Fournié-Zaluski M C
Retro-inverso concept applied to the complete inhibitors of enkephalin-degrading enzymes.
Journal of medicinal chemistry 1988;31(9):1825-31.
1986: Fournié-Zaluski M C; Belleney J; Lux B; Durieux C; Gérard D; Gacel G; Maigret B; Roques B P
Conformational analysis of cholecystokinin CCK26-33 and related fragments by 1H NMR spectroscopy, fluorescence-transfer measurements, and calculations.
Biochemistry 1986;25(13):3778-87.
1985: Roques B P; Durieux C; Gacel G; Pélaprat D; Ruiz-Gayo M; Belleney J; Fellion E; Zajac J M; Fournié-Zaluski M C; Daugé V
Studies on the conformation, enzymatic degradation, pharmacological potency, and binding properties in brain tissue of cholecystokinin-8 and new related peptides.
Annals of the New York Academy of Sciences 1985;448():61-75.
1983: Fournié-Zaluski M C; Chaillet P; Soroca-Lucas E; Marçais-Collado H; Costentin J; Roques B P
New carboxyalkyl inhibitors of brain enkephalinase: synthesis, biological activity, and analgesic properties.
Journal of medicinal chemistry 1983;26(1):60-5.
1982: Fournié-Zaluski M C; Soroca-Lucas E; Waksman G; Llorens C; Schwartz J C; Roques B P
Differential recognition of "enkephalinase" and angiotensin-converting enzyme by new carboxyalkyl inhibitors.
Life sciences 1982;31(26):2947-54.
1982: Schwartz J C; de la Baume S; Llorens C; Malfroy B; Soroca E; Fournié-Zaluski M C; Roques B P; Morgat J L; Roy J; Javoy-Agid F; Agid Y
Enkephalin dipeptidyl carboxypeptidase ("enkephalinase"): assay, properties, and distribution in human brain and exploration of the active site.
Advances in biochemical psychopharmacology 1982;33():225-34.
1982: Roques B P; Fournié-Zaluski M C; Gacel G; David M; Meunier J C; Maigret B; Morgat J L
Rational design and biological properties of highly specific mu and delta opioid peptides.
Advances in biochemical psychopharmacology 1982;33():321-31.
1981: Gacel G; Fournié-Zaluski M C; Fellion E; Roques B P
Evidence of the preferential involvement of mu receptors in analgesia using enkephalins highly selective for peripheral mu or delta receptors.
Journal of medicinal chemistry 1981;24(10):1119-24.
1980: Roques B P; Fournié-Zaluski M C; Soroca E; Lecomte J M; Malfroy B; Llorens C; Schwartz J C
The enkephalinase inhibitor thiorphan shows antinociceptive activity in mice.
Nature 1980;288(5788):286-8.
1980: Schwartz J C; de la Baume S; Malfroy B; Patey G; Perdrisot R; Swerts J P; Fournié-Zaluski M C; Gacel G; Roques B P
Properties variations and possible synaptic functions of "enkephalinase": a newly characterised dipeptidyl carboxypeptidase.
Advances in biochemical psychopharmacology 1980;22():219-35.

Sign-in to see more